Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease (2 Minute Medicine)

1. Clinical remission at 52 weeks was similar between ustekinumab and adalimumab.

2. Patient-reported outcomes of stool frequency and abdominal pain scores were lower in the ustekinumab group compared to adalimumab (p=0.019).

Evidence Rating Level: 1 (Excellent)